Compare Globus Medical Inc. Class A Common Stock (GMED) vs Exxon Mobil Corporation (XOM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Globus Medical Inc. Class A Common Stock vs Exxon Mobil Corporation — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B), while Exxon Mobil Corporation trades at $177.65 (market cap $715.80B). The key difference: Exxon Mobil Corporation is far larger — about 69.8× Globus Medical Inc. Class A Common Stock's market cap, and Exxon Mobil Corporation pays a 2.37% dividend while Globus Medical Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and Exxon Mobil Corporation for 100 Days on average.
| GMED | XOM | |
|---|---|---|
Market Cap | $10.25B | $715.80B |
Volume | 1,108,124 | 11,362,664 |
Sector | Health | Energy |
52-Week High | $96.82 | $177.06 |
52-Week Low | $58.33 | $110.64 |
Typical Hold Time | 0 Days | 100 Days |
Enterprise Value | $9.76B | $747.58B |
Dividend Yield | — | 2.37% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
ExxonMobil (XOM) trades at $172.15, up 1.9% on the day, with a bullish technical signal from moving averages but overbought RSI readings. Revenue declined to $323.91B in 2025 (SEC filing, 2025), though net income margin remains solid at 9.07%. Recent news highlights potential expansion into Venezuela's oil fields (Reuters, 2026-09-16) and operational updates in Guyana and Angola, supporting long-term growth targets.
The stock offers value with a P/E of 22.4 and strong cash flow, but faces headwinds from volatile oil prices and execution risks in new ventures. Analyst consensus is mixed with a $166.67 price target (MarketBeat, 2026-09-17), suggesting cautious optimism amid geopolitical and macroeconomic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Globus Medical Inc. Class A Common Stock
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →About Exxon Mobil Corporation
Exxon Mobil Corporation operates petroleum and petro chemicals businesses. The Company provides operations include exploration and production of oil and gas, electric power generation, and coal and minerals operations. Exxon Mobil also manufactures and markets fuels, lubricants, and chemicals. Exxon Mobil serves customers worldwide.
Read more on XOM →
